吡贝地尔缓释片联合盐酸多奈哌齐治疗对帕金森病患者认知功能及血清sLAG3、RANTES水平的影响  

Effect of piribedil sustained-release tablets combined with donepezil hydrochloride on cognitive function and serum levels of sLAG3 and RANTES in patients with Parkinson's disease

作　　者：陈晓静 程曼 张雪芳[1] 秦慧兵[1] 刘红钊[1] CHEN Xiao-jing;CHENG Man;ZHANGXue-fang;QIN Hui-bing;LIU Hong-zhao(Department of Neurology,Nanyang Central Hospital,Nanyang 473000,Henan,CHINA)

机构地区：[1]南阳市中心医院神经内科,河南南阳473000

出　　处：《海南医学》2023年第18期2590-2594,共5页Hainan Medical Journal

基　　金：2020年河南省医学科技攻关项目(编号:LHGJ20201596)。

摘　　要：目的研究吡贝地尔缓释片联合盐酸多奈哌齐治疗对帕金森病(PD)患者认知功能及血清可溶性淋巴细胞活化基因3(sLAG3)、活化T细胞趋化因子(RANTES)水平的影响。方法选取2020年3月至2022年10月南阳市中心医院神经内科收治的134例PD患者为研究对象,采用随机数表法分为对照组和联合组各67例。对照组患者采用盐酸多奈哌齐治疗,联合组患者采用吡贝地尔缓释片联合盐酸多奈哌齐治疗,均治疗3个月。治疗后比较两组患者的临床疗效,以及治疗前、治疗1个月、3个月后的帕金森综合评分量表-Ⅲ(UPDRS-Ⅲ)、智力状态检查量表(MMSE)、帕金森病睡眠障碍量表(PDSS)评分、血清神经递质[脑源性神经营养因子(BDNF)、5-羟色胺(5-HT)、神经元特异性烯醇化酶(NSE)、去甲肾上腺素(NE)]和血清白介素-6(IL-6)、白介素-1β(IL-1β)、sLAG3、RANTES水平,同时比较两组患者治疗期间的不良反应发生情况。结果联合组患者的临床治疗总有效率为94.03%,明显高于对照组的82.09%,差异有统计学意义(P<0.05);治疗1个月、3个月后,联合组患者的UPDRS-Ⅲ评分明显低于对照组,MMSE、PDSS评分明显高于对照组,差异均有统计学意义(P<0.05);治疗1个月、3个月后,联合组患者的血清BDNF、5-HT、NE水平明显高于对照组,NSE水平明显低于对照组,差异均有统计学意义(P<0.05);治疗1个月、3个月后,联合组患者的血清IL-6、IL-1β、sLAG3、RANTES水平明显低于对照组,差异均有统计学意义(P<0.05);治疗期间联合组患者的不良反应总发生率为5.79%,略高于对照组的1.49%,但差异无统计学意义(P>0.05)。结论吡贝地尔缓释片联合盐酸多奈哌齐治疗PD可有效改善患者的神经功能、运动功能、认知功能、睡眠质量,提高临床疗效,且安全性较高。Objective To investigate the effects of piribedil sustained-release tablets combined with donepezil hydrochloride on cognitive function and serum levels of soluble lymphocyte activating gene 3(sLAG3)and activated T-cell chemokines(RANTES)in patients with Parkinson's disease(PD).Methods A total of 134 PD patients admitted to Department of Neurology,Nanyang Central Hospital from March 2020 to October 2022 were selected as the study subjects.They were randomly divided into a control group and a combination group,with 67 patients in each group.Patients in the control group were treated with donepezil hydrochloride,while patients in the combination group were treated with piribedil sustained-release tablets combined with donepezil hydrochloride,both for 3 months.The clinical efficacy were compared between the two groups,as well as Unified Parkinson’s Disease Rating Scale Ⅲ(UPDRSⅢ),Mini-mental State Examination(MMSE),Parkinson's Disease Sleep Scale(PDSS)scores,serum neurotransmitters[brain-derived neurotrophic factor(BDNF),5-hydroxytryptamine(5-HT),neuron-specific enolase(NSE),and norepinephrine(NE)],and levels of interleukin-6(IL-6),interleukin-1β(IL-1β),sLAG3,and RANTES before treatment,1 month,and 3 months after treatment.At the same time,the occurrence of adverse reactions during treatment was compared between the two groups.Results The total clinical effective rate of the combination group was 94.03%,significantly higher than 82.09% in the control group(P<0.05).After 1 month and 3 months of treatment,the UPDRSⅢ scores in the combination group were significantly lower than those in the control group,and the scores of MMSE and PDSS scores were significantly higher than those in the control group,with statistically significant differences(P<0.05).After 1 month and 3 months of treatment,the serum levels of BDNF,5-HT,and NE in the combination group were significantly higher than those in the control group,and NSE level was significantly lower than that in the control group,with statistically significant diffe

关 键 词：帕金森病 吡贝地尔缓释片 盐酸多奈哌齐 认知功能 疗效 

分 类 号：R742.5[医药卫生—神经病学与精神病学]